Effects of human recombinant growth hormone on donor-site healing in burned adults.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Patients suffering severe burns have an accelerated catabolism with a highly negative nitrogen balance that may worsen their prognosis.

In the existing literature there are no controlled prospective clinical trials in adult patients that confirm these data.

Who Took Part

The study group was 24 patients.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

What Was Measured

PubMed files the paper under topics including Burn Units, Burns, Cyclic AMP Receptor Protein, Human Growth Hormone, Length of Stay, Recombinant Proteins and Skin Transplantation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 24 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2002 (World journal of surgery), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.